Catheter Precision (VTAK) 10-Q 15 Nov 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 10, 2021
Cover [Abstract]
Entity Registrant Name	Ra Medical Systems, Inc.
Entity Central Index Key	0001716621
Document Type	10-Q
Document Period End Date	Sep. 30, 2021
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	RMED
Security Exchange Name	NYSEAMER
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		7,029,765
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Ex Transition Period	false
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	001-38677
Entity Tax Identification Number	38-3661826
Entity Address, Address Line One	2070 Las Palmas Drive
Entity Address, City or Town	Carlsbad
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92011
City Area Code	760
Local Phone Number	804-1648
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	DE
Entity Interactive Data Current	Yes

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current Assets
Cash and cash equivalents	$ 20,616	$ 23,906
Accounts receivable, net	17	24
Inventories	997	877
Prepaid expenses and other current assets	1,169	1,100
Current assets of discontinued operations		1,713
Total current assets	22,799	27,620
Property and equipment, net	2,030	2,527
Operating lease right-of-use assets	2,205	2,484
Other long-term assets	45	45
Long-term assets of discontinued operations		762
TOTAL ASSETS	27,079	33,438
Current Liabilities
Accounts payable	543	471
Accrued expenses	2,632	4,147
Current portion of operating lease liabilities	301	356
Current portion of equipment financing		265
Current portion of PPP promissory note		421
Current liabilities of discontinued operations		2,102
Total current liabilities	3,476	7,762
Operating lease liabilities	2,054	2,264
PPP promissory note		1,579
Long-term liabilities of discontinued operations		686
Total liabilities	5,530	12,291
Commitments and contingencies (Note 14)
Stockholders’ Equity
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares issued
Common stock, $0.0001 par value; 300,000 shares authorized; 7,042 and 3,189 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively	7	7
Additional paid-in capital	191,527	174,342
Accumulated deficit	(169,985)	(153,202)
Total stockholders’ equity	21,549	21,147
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 27,079	$ 33,438

Condensed Balance Sheets (Una_2

Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	7,042,000	3,189,000
Common stock, shares outstanding	7,042,000	3,189,000

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Net revenues
Total net revenues	$ 5	$ 68	$ 17	$ 259
Cost of revenues
Total cost of revenues	246	568	1,213	1,746
Gross loss	(241)	(500)	(1,196)	(1,487)
Operating expenses
Selling, general and administrative	4,211	4,695	11,285	18,154
Research and development	2,942	2,312	8,521	5,534
Total operating expenses	7,153	7,007	19,806	23,688
Operating loss	(7,394)	(7,507)	(21,002)	(25,175)
Other income (expense), net
Other income (expense), net	16	(8)	5	97
Gain on extinguishment of PPP promissory note			2,023
Total other income (expense), net	16	(8)	2,028	97
Loss from continuing operations before income taxes	(7,378)	(7,515)	(18,974)	(25,078)
Loss from continuing operations	(7,378)	(7,515)	(18,974)	(25,078)
Discontinued operations (Note 3)
Income (loss) from discontinued operations (including gain on sale of $3,500 in 2021) before income taxes	3,080	(264)	2,191	(523)
Income (loss) from discontinued operations	3,080	(264)	2,191	(523)
Net loss	$ (4,298)	$ (7,779)	$ (16,783)	$ (25,601)
Net (loss) income per share, basic and diluted
Continuing operations	$ (1.15)	$ (3.15)	$ (4.23)	$ (19.32)
Discontinued operations	0.48	(0.11)	0.49	(0.40)
Total net loss per share, basic and diluted	$ (0.67)	$ (3.26)	$ (3.74)	$ (19.72)
Weighted average number of shares used in computing net income (loss) per share, basic and diluted	6,415	2,386	4,487	1,298
Product Sales [Member]
Net revenues
Total net revenues	$ 5	$ 66	$ 17	$ 254
Cost of revenues
Total cost of revenues	68	323	676	1,131
Service and Other [Member]
Net revenues
Total net revenues		2		5
Cost of revenues
Total cost of revenues	$ 178	$ 245	$ 537	$ 615

Condensed Statements of Opera_2

Condensed Statements of Operations (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Income Statement [Abstract]
Gain on sale of business	$ 3,473	$ 3,473

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (4,298)	$ (7,779)	$ (16,783)	$ (25,601)
Other comprehensive loss:
Unrealized losses related to short-term investments				(26)
Comprehensive loss	$ (4,298)	$ (7,779)	$ (16,783)	$ (25,627)

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (16,783)	$ (25,601)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on sale of discontinued operations	(3,473)
Gain on extinguishment of PPP promissory note	(2,023)
Stock-based compensation	1,967	3,044
Depreciation and amortization	1,250	1,845
(Gain) loss on sales and disposals of property and equipment	(489)	64
Provision for doubtful accounts		25
Changes in operating assets and liabilities:
Accounts receivable	93	286
Inventories	(262)	78
Prepaid expenses and other assets	9	1,437
Accounts payable	171	(633)
Accrued expenses	(1,875)	1,678
Deferred revenue	(234)	(876)
Other liabilities	(265)	(237)
Net cash used in operating activities	(21,914)	(18,890)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from sale of discontinued operations	3,700
Payment of fees related to sale of discontinued operations	(227)
Proceeds from sales of property and equipment	554
Purchases of property and equipment	(224)	(72)
Proceeds from maturities of available-for-sale securities		16,000
Net cash provided by investing activities	3,803	15,928
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock and warrants, net	15,430	19,887
Payments of offering costs related to the issuance of common stock and warrants	(370)	(499)
Payments on equipment financing	(265)	(218)
Proceeds from purchases under employee stock purchase plan	26	27
Proceeds from PPP promissory note		2,000
Proceeds from issuance of common stock in connection with the exercise of warrants		827
Net cash provided by financing activities	14,821	22,024
NET CHANGE IN CASH AND CASH EQUIVALENTS	(3,290)	19,062
CASH AND CASH EQUIVALENTS, beginning of period	23,906	14,584
CASH AND CASH EQUIVALENTS, end of period	20,616	33,646
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Unpaid property and equipment	26
Unpaid offering costs		281
Transfer of lasers from inventories to property and equipment		107
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash payments for interest	2	$ 23
Cash payments for taxes	$ 2

Condensed Statements of Stockho

Condensed Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Balances at Dec. 31, 2019	$ 33,150	$ 1	$ 150,280	$ 26	$ (117,157)
Balance (in shares) at Dec. 31, 2019		551
Common stock issued (in shares)		5
Stock-based compensation	1,047		1,047
Other comprehensive loss	(22)			(22)
Net loss	(7,701)				(7,701)
Balances at Mar. 31, 2020	26,474	$ 1	151,327	4	(124,858)
Balance (in shares) at Mar. 31, 2020		556
Balances at Dec. 31, 2019	33,150	$ 1	150,280	26	(117,157)
Balance (in shares) at Dec. 31, 2019		551
Net loss	(25,601)
Balances at Sep. 30, 2020	30,538	$ 7	173,289		(142,758)
Balance (in shares) at Sep. 30, 2020		2,898
Balances at Mar. 31, 2020	26,474	$ 1	151,327	4	(124,858)
Balance (in shares) at Mar. 31, 2020		556
Common stock issued, net	5,284	$ 2	5,282
Common stock issued (in shares)		889
Warrants issued, net	3,464		3,464
Exercise of warrants	827	$ 1	826
Exercise of warrants (in shares)		73
Common stock issued pursuant to the vesting of restricted stock units and employee stock purchase plan	27		27
Common stock issued pursuant to the vesting of restricted stock units and employee stock purchase plan (in shares)		9
Stock-based compensation	1,033		1,033
Other comprehensive loss	(4)			$ (4)
Net loss	(10,121)				(10,121)
Balances at Jun. 30, 2020	26,984	$ 4	161,959		(134,979)
Balance (in shares) at Jun. 30, 2020		1,527
Common stock issued, net	6,341	$ 3	6,338
Common stock issued (in shares)		1,371
Warrants issued, net	4,028		4,028
Stock-based compensation	964		964
Net loss	(7,779)				(7,779)
Balances at Sep. 30, 2020	30,538	$ 7	173,289		(142,758)
Balance (in shares) at Sep. 30, 2020		2,898
Balances at Dec. 31, 2020	21,147	$ 7	174,342		(153,202)
Balance (in shares) at Dec. 31, 2020		3,189
Common stock issued, net	65		65
Common stock issued (in shares)		35
Stock-based compensation	1,169		1,169
Stock-based compensation (In shares)		35
Net loss	(7,236)				(7,236)
Balances at Mar. 31, 2021	15,145	$ 7	175,576		(160,438)
Balance (in shares) at Mar. 31, 2021		3,259
Balances at Dec. 31, 2020	21,147	$ 7	174,342		(153,202)
Balance (in shares) at Dec. 31, 2020		3,189
Net loss	(16,783)
Balances at Sep. 30, 2021	21,549	$ 7	191,527		(169,985)
Balance (in shares) at Sep. 30, 2021		7,042
Balances at Mar. 31, 2021	15,145	$ 7	175,576		(160,438)
Balance (in shares) at Mar. 31, 2021		3,259
Common stock issued, net	10,645		10,645
Common stock issued (in shares)		2,582
Common stock issued pursuant to the vesting of restricted stock units and employee stock purchase plan	26		26
Common stock issued pursuant to the vesting of restricted stock units and employee stock purchase plan (in shares)		6
Stock-based compensation	696		696
Stock-based compensation (In shares)		56
Net loss	(5,249)				(5,249)
Balances at Jun. 30, 2021	21,263	$ 7	186,943		(165,687)
Balance (in shares) at Jun. 30, 2021		5,903
Common stock issued, net	4,350		4,350
Common stock issued (in shares)		1,139
Warrants issued, net	132		132
Stock-based compensation	102		102
Net loss	(4,298)				(4,298)
Balances at Sep. 30, 2021	$ 21,549	$ 7	$ 191,527		$ (169,985)
Balance (in shares) at Sep. 30, 2021		7,042

Organization and Nature of Oper

Organization and Nature of Operations	9 Months Ended
	Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Nature of Operations	Note 1. Organization and Nature of Operations The Company Ra Medical Systems, Inc. (the “Company”) is a medical device company that develops, manufactures and markets an advanced excimer laser and single-use catheter system, together referred to as “DABRA”, used by physicians as a tool in the treatment of peripheral artery disease (“PAD”). The Company was formed on September 4, 2002 in the state of California and reincorporated in Delaware on July 14, 2018. On August 16, 2021, the Company completed the sale of its Pharos dermatology business (the “Dermatology Business”). As a result, the Company has reported the operating results of the Dermatology Business as discontinued operations in the condensed statements of operations for all periods presented. In addition, the related assets and liabilities associated with the Dermatology Business were reported as assets of discontinued operations and liabilities of discontinued operations in the condensed balance sheets. Unless otherwise noted, discussion within these notes to the unaudited condensed financial statements relates to continuing operations. See Note 3. Discontinued Operations Reverse Stock Split On November 16, 2020, the Company filed a certificate of amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware to affect a reverse stock split of the Company’s common stock at a ratio of one-for-twenty-five (“Reverse Stock Split”). The Reverse Stock Split became effective as of 4:01 p.m. Eastern time on November 16, 2020, and the Company’s common stock began trading on the New York Stock Exchange on a post-split basis on November 17, 2020. Unless otherwise noted, all share and per share numbers contained in these financial statements are reflected on a post-split basis. COVID-19 and Market Conditions The global spread of the novel coronavirus (“COVID-19”) has created significant volatility, uncertainty and economic disruption. The ultimate effects of COVID-19 on the Company’s business, operations and financial condition are unknown at this time. In the near term, the Company expects that enrollment in its atherectomy clinical trial will continue to be slowed, as patients elect to postpone voluntary treatments and many physicians’ offices have been either closed or operating at a reduced capacity. The Company’s manufacturing facility located in Carlsbad, California is currently operational. The Company has experienced delays in receiving shipments of parts which has had an impact on the timing of its key engineering efforts but has not affected its ability to support its atherectomy clinical study. However, the extent to which COVID-19 impacts its business will depend on future developments which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the actions to contain it or treat its impact, among others. The Company is also experiencing increased difficulty in attracting and retaining key personnel due to a tight labor market. Going Concern The Company has experienced recurring net losses from operations and negative cash flows from operating activities, has a significant accumulated deficit and expects to continue to incur net losses into the foreseeable future. The Company had an accumulated deficit of $170.0 million at September 30, 2021. For the nine months ended September 30, 2021, the Company used cash of $21.9 million in operating activities from continuing and discontinued operations. As of September 30, 2021, the Company had cash and cash equivalents of $20.6 million. Management expects operating losses and negative cash flows to continue for the foreseeable future with the Company’s reduced commercial footprint, and as the Company continues to incur costs related to its atherectomy clinical trial, engineering efforts to improve the shelf life of its catheters and develop next generation products and legal costs associated with ongoing litigation. In September 2020, the Company paused commercial sales of the DABRA catheter not being used for the atherectomy clinical trial while it conducted further studies on the stability of its shelf life. The Company submitted additional test data with respect to the DABRA catheter shelf life in March 2021, which was cleared by the U.S. Food and Drug Administration in July 2021. Although eligible, the Company has not resumed commercial sales and is evaluating its commercial catheter strategy. The Company also expects the COVID-19 pandemic to have a continued negative impact on the timing of enrollment in its atherectomy clinical trial as well as the Company’s ability to secure additional financing in a timely manner or on favorable terms, if at all. Management believes that, based on the Company’s liquidity resources, there is substantial doubt about the Company’s ability to continue as a going concern for a period of at least 12 months from the date of issuance of the financial statements. Although the Company bolstered its liquidity resources in 2021 and 2020 , has an effective shelf registration statement and an “at the market” (“ATM”) offering to allow it to raise additional capital when the opportunities permit and may receive additional funds from the exercise of its warrants depending on market conditions, management has concluded that the aforementioned conditions, including the ongoing uncertainty related to the negative impacts of the COVID-19 pandemic, continue to raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least 12 months from the date of issuance of the financial statements. Management plans to address this uncertainty by raising additional fund s , if necessary, through public or private equity or debt financings as well as by engaging in regular and ongoing reviews of its business model and strategic options to help ensure that the Company is focusing its cash resources on advancing its key corporate initiatives. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of this uncertainty.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Significant Accounting Policies Basis of Presentation The unaudited interim condensed financial statements have been prepared on the same basis as the annual financial statements and reflect all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company’s condensed balance sheets, results of operations, cash flows and statements of stockholders’ equity for the periods presented. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any other future annual or interim period. The balance sheet as of December 31, 2020 included herein was derived from the audited financial statements as of that date after reclassifications related to discontinued operations. These unaudited condensed financial statements should be read in conjunction with the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 17, 2021. Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. Use of estimates The unaudited condensed financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States (“GAAP”). Fair Value Measurements Fair value represents the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants and is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. A three-tier value hierarchy is used to identify inputs used in measuring fair value as follows: Level 1 – Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; Level 2 – Inputs other than the quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and Level 3 – Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions. The hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company measures its cash and cash equivalents and short-term investments at fair value. Inventories Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. Cost includes materials, labor and manufacturing overhead related to the purchase and production of inventories. The Company reduces the carrying value of inventories for those items that are potentially excess or obsolete based on changes in customer demand, technological developments or other economic factors. Catheters are manufactured in-house, and each catheter is tested at various stages of the manufacturing process for adherence to quality standards. Catheters that do not meet functionality specification at each test point are destroyed and immediately written off, with the expense recorded in cost of revenue in the statements of operations. Once manufactured, completed catheters that pass quality assurance are sent to a third-party for sterilization and sealed in a sterile container. Upon return from the third-party sterilizer, a sample of catheters from each batch are re-tested. If the sample tests are successful, the batch is accepted into finished goods inventory. If the sample tests are unsuccessful, the entire batch is written off with the expense recorded in cost of revenue in the statements of operations. Revenue The Company generates revenue from the sales of products and services. Product sales consist of the sales of catheters for use with the DABRA laser system. The Company has paused selling commercial product and is only selling catheters for use in the atherectomy clinical trial. The Company’s sales agreements generally do not include right-of-return provisions for any form of consideration, including partial refund or credit against amounts owed to the Company. Services and other revenue primarily consist of billable services, including fees related to DABRA laser commercial usage agreements. Catheter Revenue When engaged in commercial sales, the Company enters into a DABRA laser commercial usage agreement or DABRA laser placement acknowledgement with each customer that is supplied a DABRA laser, collectively the “usage agreement”, which provides for specific terms of continued use of the DABRA laser, including a nominal periodic fee. The terms of a usage agreement typically allow the Company to place a DABRA laser at a customer’s specified location without a specified contract term. Under the usage agreement terms, the Company retains all ownership rights to the DABRA laser and is permitted to request the return of the equipment within 10 business days of notification. While the periodic fees are nominal, the usage agreement provides the Company the exclusive rights to supply related single-use catheters to the customer which aggregate the majority of the product sales revenue. There are no specified minimum purchase commitments for the catheters. The Company recognizes revenue associated with the usage agreements and catheter supply arrangements in accordance with Financial Accounting Standards Board (“FASB”) “ Revenue from Contracts with Customers (Topic 606),” Distributor Transactions In certain markets outside the U.S., the Company sold products and provided services to customers through distributors that specialize in medical device products. The terms of sales transactions through distributors were generally consistent with the terms of direct sales to customers. The Company accounted for these transactions in accordance with the Company’s revenue recognition policy described herein. The following accounting policies are specifically related to the Company’s discontinued operations: Laser Sales The Company recognized revenue on laser sales at the point in time that control transferred to the customer. Control of the product typically transferred upon shipment. Warranty Service Revenue The Company typically provided a 12-month warranty with the purchase of its laser systems. Customers could extend the warranty period through the purchase of extended warranty service contracts. Extended warranty service contracts were sold with contract terms ranging from 12 to 60 months and covered periods after the end of the initial 12-month warranty period. The warranty provided the customer with maintenance services in addition to the assurance that the laser product complied with agreed-upon specifications. Therefore, the warranty service was treated as a separate performance obligation from the laser system. Warranty services were a stand-ready obligation, and the Company recognized revenue on a straight-line basis over the service contract term. Warranty service revenue was included in service and other revenue. Contract Costs The Company capitalized costs to obtain contracts that were considered incremental and recoverable, such as sales commissions. The capitalized costs were amortized to selling, general and administrative expense over the estimated period of benefit of the asset, which was the contract term. The Company elected to use the practical expedient to expense the costs to obtain a contract when the amortization period was less than one year. These lease arrangements contained one lease component (the laser) and one non-lease component (warranty service) for which the Company elected the practical expedient to not separate the non-lease component from the lease component. The Company accounted for the combined lease component as an operating lease and recognized lease income on a straight-line basis over the lease term. Rental Income The Company also derived income pursuant to its product operating lease agreements for its Pharos laser systems, prior to the sale of the Dermatology Business. Consequently, the Company retained title to the equipment. Depreciation expense on the leased lasers was recorded to cost of revenues on a straight-line basis. The costs to maintain the leased lasers were charged to cost of revenues as incurred. These lease arrangements contained one lease component (the laser) and one non-lease component (warranty service) for which the Company elected the practical expedient to not separate the non-lease component from the lease component. The Company accounted for the combined lease component as an operating lease and recognized lease income on a straight-line basis over the lease term. Segment Information After the sale of the Dermatology Business, the Company began operating its business in one segment, which includes all activities related to the research, development and manufacture of the DABRA system. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company has evaluated recently issued accounting pronouncements and, based on its preliminary assessment, does not believe any will have a material impact on the condensed financial statements or related footnote disclosures.

Discontinued Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2021
Payables And Accruals [Abstract]
Discontinued Operations	Note 3. Discontinued Operations Consistent with the Company’s continued focus on the PAD market, the Company completed the sale of its Dermatology Business to Strata Skin Sciences, Inc. (“Strata”) on August 16, 2021 for cash proceeds of $3.7 million. The Company paid broker and legal fees of approximately $0.2 million related to the sale of the Dermatology Business. In addition, the Company issued a warrant to the broker to purchase 74,247 shares of common stock at an exercise price of $2.99 per share. The warrant is immediately exercisable and expires five years following the date of issuance. The warrant was valued at approximately $0.1 million on the grant date using the Black-Scholes option pricing model based on the following assumptions: expected volatility of 104.55%, risk-free interest rate of 0.32%, expected dividend yield of 0% and an expected term of 2.5 years. The Dermatology Business was previously disclosed as a separate reportable segment of the Company. The sale of the Dermatology Business resulted in a gain of $3.5 million which is included as a component of income (loss) from discontinued operations in the condensed statements of operations for the three and nine months ended September 30, 2021. Beginning in the third quarter of 2021, the Company has reported the results of the Dermatology Business in income (loss) from discontinued operations in the condensed statements of operations and excluded them from continuing operations for all periods presented. The assets and liabilities of the Dermatology Business are recorded as assets of discontinued operations and liabilities of discontinued operations, respectively, in the condensed balance sheets. Certain overhead costs previously allocated to the Dermatology Business for segment reporting purposes did not qualify for classification within discontinued operations and have been reallocated to continuing operations for all periods presented. The following table summarizes the carrying amounts of the assets and liabilities included as discontinued operations in the condensed balance sheet at December 31, 2020 (in thousands): December 31, 2020 Assets of discontinued operations Accounts receivable, net $ 214 Inventories 1,341 Prepaid expenses and other current assets 158 Property and equipment, net 684 Other long-term assets 78 Total assets of discontinued operations $ 2,475 Liabilities of discontinued operations Accounts payable $ 100 Accrued expenses 201 Deferred revenue 2,487 Total liabilities of discontinued operations $ 2,788 The assets and liabilities of discontinued operations have been classified as current and long-term, as applicable, in the condensed balance sheet at December 31, 2020. The following table summarizes the major classes of items constituting income (loss) from discontinued operations in the condensed statements of operations for each of the periods presented (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Net revenues Product sales $ 140 $ 118 $ 852 $ 670 Service and other 349 729 1,748 2,259 Total net revenues 489 847 2,600 2,929 Cost of revenues Product sales 158 347 1,201 1,127 Service and other 238 504 1,089 1,296 Total cost of revenues 396 851 2,290 2,423 Gross income (loss) 93 (4 ) 310 506 Operating expenses Selling, general and administrative 330 236 1,110 958 Research and development 134 21 388 47 Total operating expenses 464 257 1,498 1,005 Operating loss (371 ) (261 ) (1,188 ) (499 ) Interest expense, net (22 ) (3 ) (94 ) (24 ) Loss from discontinued operations (393 ) (264 ) (1,282 ) (523 ) Gain on sale of the Dermatology Business 3,473 — 3,473 — Income (loss) from discontinued operations $ 3,080 $ (264 ) $ 2,191 $ (523 ) Depreciation expense for the Dermatology Business was $0.1 million for each of the three months ended September 30, 2021 and 2020 and $0.3 million for each of the nine months ended September 30, 2021 and 2020. There were no capital expenditures for the Dermatology Business during the nine months ended September 30, 2021 and 2020. Stock-based compensation expense for the Dermatology Business was de minimis and approximately $14,000 for the three months ended September 30, 2021 and 2020, respectively. Stock-based compensation expense was approximately $18,000 and $0.1 million for the nine months ended September 30, 2021 and 2020, respectively. Stock-based compensation expense of approximately $4,000 and $30,000 was capitalized to inventory and property and equipment during the three months ended September 30, 2021 and 2020, respectively. Stock-based compensation expense of approximately $0.1 million was capitalized to inventory and property and equipment during each of the nine months ended September 30, 2021 and 2020.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 4. Fair Value Measurements Cash equivalents of approximately $9.4 million and $18.4 million at September 30, 2021 and December 31, 2020, respectively, were comprised of money market funds which were measured at fair value on a recurring basis based on Level 1 of the fair value hierarchy.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Inventories	Inventories consisted of the following (in thousands): September 30, 2021 December 31, 2020 Raw materials $ 884 $ 547 Work in process 60 270 Finished goods 53 60 Total inventories $ 997 $ 877

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2021
Property Plant And Equipment Net [Abstract]
Property and Equipment	Note 6. Property and Equipment Property and equipment consisted of the following (in thousands): September 30, 2021 December 31, 2020 Lasers $ 3,151 $ 3,194 Machinery and equipment 812 834 Computer hardware and software 353 353 Construction in progress 209 51 Leasehold improvements 119 119 Automobiles 62 1,054 Furniture and fixtures 48 48 Property and equipment, gross 4,754 5,653 Accumulated depreciation (2,724 ) (3,126 ) Total property and equipment, net $ 2,030 $ 2,527 Depreciation expense was $0.2 million and $0.4 million for the three months ended September 30, 2021 and 2020, respectively, and $0.7 million and $1.3 million for the nine months ended September 30, 2021 and 2020, respectively

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2021
Payables And Accruals [Abstract]
Accrued Expenses	Note 7. Accrued Expenses Accrued expenses consisted of the following (in thousands): September 30, 2021 December 31, 2020 Accrued legal expenses $ 1,393 $ 957 Compensation and related benefits 496 2,479 Accrued warranty (Note 8) 195 204 Other accrued expenses 548 507 Total accrued expenses $ 2,632 $ 4,147

Accrued Warranty

Accrued Warranty	9 Months Ended
	Sep. 30, 2021
Product Warranties Disclosures [Abstract]
Accrued Warranty	Note 8. Accrued Warranty Activity in the warranty accrual is included in accrued expenses in the condensed balance sheets and consisted of the following (in thousands): Nine Months Ended September 30, 2021 Year Ended December 31, 2020 Balance at beginning of period $ 204 $ 234 Increase in warranty accrual — 19 Change in liability for pre-existing warranties — 4 Claims satisfied (9 ) (53 ) Total accrued warranty $ 195 $ 204 The accrued warranty balances at September 30, 2021 and December 31, 2020 each included $0.1 million related to the voluntary recall of catheters, which occurred in September 2019.

Paycheck Protection Program Pro

Paycheck Protection Program Promissory Note	9 Months Ended
	Sep. 30, 2021
Paycheck Protection Program Promissory Note [Abstract]
Paycheck Protection Program Promissory Note	Note 9. Paycheck Protection Program Promissory Note In May 2020, the Company entered into a $2.0 million Paycheck Protection Program Promissory Note and Agreement (“PPP Promissory Note”) with a commercial bank under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). The PPP Promissory Note bore an interest rate of 1.0% per annum. Under the terms of the PPP Promissory Note, payments would have been due monthly beginning November 1, 2020, and the principal amount of the PPP Promissory Note, along with any unpaid interest, would have been due in May 2022. On June 5, 2020, the Paycheck Protection Program Flexibility Act of 2020 extended the deferral period for all loans to 10 months after the last day of the covered period. Under the revised terms, payments would have been due beginning August 2021, and the principal amount, along with unpaid interest, would have been due in May 2022. The principal and interest could be forgiven if the proceeds were used for forgivable purposes as defined by the terms in the PPP Promissory Note. The Company applied for full forgiveness under the provisions of the CARES Act in March 2021 and received approval by the Small Business Administration on June 24, 2021. Gain on extinguishment of the PPP Promissory Note of $2.0 million was included in other income (expense), net in the condensed statement of operations for the nine months ended September 30, 2021. Interest expense on the PPP Promissory Note for the three months ended September 30, 2021 and 2020 was nil and approximately $5,000, respectively. Interest expense on the PPP Promissory Note for the nine months ended September 30, 2021 and 2020 was approximately $10,000 and $8,000, respectively.

Leases

Leases	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Leases	Note 10. Leases The Company has two operating leases for office and manufacturing space which require it to pay base rent and certain utilities. Monthly rent expense is recognized on a straight-line basis over the terms of the leases, which expire in 2027 and December 2021. At September 30, 2021, the weighted average remaining lease term was 6.3 years. The operating leases are included in the condensed balance sheets at the present value of the lease payments at a 7% discount rate which approximates the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment, as the leases do not provide an implicit rate. For each of the three months ended September 30, 2021 and 2020, operating lease expense and cash paid for leases was $0.1 million. For each of the nine months ended September 30, 2021 and 2020, operating lease expense and cash paid for leases was $0.4 million. Amortization for operating lease right-of-use assets was $0.1 million for each of the three months ended September 30, 2021 and 2020 and Maturities of operating lease liabilities as of September 30, 2021 were as follows (in thousands): Years Ending December 31, 2021 (remaining three months) $ 132 2022 432 2023 445 2024 459 2025 472 2026 486 Thereafter 501 Total operating lease payments 2,927 Less: imputed interest (572 ) Total operating lease liabilities $ 2,355

Net Loss per Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Net Loss per Share	Note 11. Net Loss per Share The Company calculates basic net loss per share by dividing net loss by the weighted average number of common shares outstanding during the reporting period. A net loss cannot be diluted, so when the Company is in a net loss position, basic and diluted loss per common share are the same. If in the future the Company achieves profitability, the denominator of a diluted earnings per common share calculation will include both the weighted average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents include warrants, stock options and non-vested restricted stock awards and restricted stock units using the treasury stock method, along with the effect, if any, from outstanding convertible securities. The Company’s outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company. Anti-dilutive share equivalents excluded from the computation of diluted net loss per share at September 30, 2021 consisted of warrants of 2,419,280, stock options of 126,998, restricted stock awards of 312,380, restricted stock units of 45,832 and Employee Stock Purchase Plan shares of 10,462. Anti-dilutive share equivalents excluded from the computation of diluted net loss per share at September 30, 2020 consisted of warrants of 2,345,033, stock options of 144,851, restricted stock awards of 5,000, restricted stock units of 20,678 and Employee Stock Purchase Plan shares of 3,772.

Equity Offerings

Equity Offerings	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Equity Offerings	Note 12. Equity Offerings In February 2021, the Company completed an ATM offering of 35,768 shares of common stock at a price of $8.39 per share. The Company received approximately $0.3 million in net proceeds, after deducting placement agent’s fees. The Company also incurred $0.2 million in offering fees and other expenses in association with filing the related Registration Statement on Form S-3 with the SEC. On various dates in May 2021 and June 2021, the Company completed ATM offerings of 2,582,019 shares of common stock at a weighted average price of $4.29 per share. The Company received approximately $10.6 million in net proceeds, after deducting placement agent’s fees. On various dates in July 2021 and August 2021, the Company completed ATM offerings of 1,139,306 shares of common stock, at a weighted average price of $4.00 per share. The Company received approximately $4.4 million in net proceeds, after deducting offering fees.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	Note 13. Stock-Based Compensation A summary of the stock option activity under the 2018 Equity Incentive Plan (the “ 2018 Plan”) 2018 Stock Compensation Plan Stock Options Weighted Average Exercise Price Weighted Average Remaining Life (in years) Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2020 124,171 $ 363.31 6.42 Forfeited (15,173 ) $ 87.28 Outstanding at September 30, 2021 108,998 $ 401.74 4.82 $ — Exercisable at September 30, 2021 95,096 $ 455.95 4.32 $ — Vested and expected to vest at September 30, 2021 108,998 $ 401.74 4.80 $ — A summary of the stock option activity under the 2020 Inducement Equity Incentive Plan (the “2020 Plan”) is presented below: Stock Options Weighted Average Exercise Price Weighted Average Remaining Life (in years) Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2020 18,000 $ 25.50 9.24 Outstanding at September 30, 2021 18,000 $ 25.50 8.50 $ — Exercisable at September 30, 2021 6,750 $ 25.50 8.50 $ — Vested and expected to vest at September 30, 2021 18,000 $ 25.50 8.50 $ — A summary of the restricted stock unit activity under the 2018 Plan is presented below: Restricted Stock Units Weighted Average Grant Date Fair Value Outstanding at December 31, 2020 33,548 $ 21.93 Granted 29,614 $ 3.99 Vested (1,845 ) $ 64.80 Forfeited (15,485 ) $ 14.67 Outstanding at September 30, 2021 45,832 $ 11.06 A summary of the restricted stock award activity under the 2018 Plan is presented below: Restricted Stock Awards Weighted Average Grant Date Fair Value Outstanding at December 31, 2020 286,161 $ 4.77 Granted 103,939 $ 4.82 Vested (31,388 ) $ 6.96 Forfeited (50,082 ) $ 5.10 Outstanding at September 30, 2021 308,630 $ 4.51 A summary of the restricted stock award activity under the 2020 Plan is presented below: Restricted Stock Awards Weighted Average Grant Date Fair Value Outstanding at December 31, 2020 4,375 $ 25.50 Vested (625 ) $ 25.50 Outstanding at September 30, 2021 3,750 $ 25.50 Stock-based compensation expense recorded in operating expenses was as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Selling, general and administrative $ 78 $ 757 $ 1,551 $ 2,424 Research and development 27 115 251 317 Stock-based compensation in operating expenses $ 105 $ 872 $ 1,802 $ 2,741 Stock-based compensation expense of approximately Stock-based compensation of approximately $ 0.1 million Unrecognized compensation expense for stock options issued as of September 30, 2021 was $0.4 million and is expected to be recognized over a weighted average period of 1.9 years. Unrecognized compensation expense for the restricted stock units as of September 30, 2021 was $0.3 million and is expected to be recognized over a weighted average period of 2.0 years. Unrecognized compensation expense for the restricted stock awards as of September 30, 2021 was $0.8 million and is expected to be recognized over a weighted average period of 2.4 years.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 14. Commitments and Contingencies Legal In the normal course of business, the Company is at times subject to pending and threatened legal actions. In management’s opinion, any potential loss resulting from the resolution of these matters will not have a material effect on the results of operations, financial position or cash flows of the Company. Securities Litigation On June 7, 2019, a putative securities class action complaint captioned Derr v. Ra Medical Systems, Inc., et. al., The court has not yet ruled on defendants’ motion to dismiss. On November 12, 2021, following a private settlement mediation with the lead plaintiffs, the parties executed a stipulation of settlement that resolved the claims asserted in the securities class action. The settlement provides for a payment to the plaintiff class of $10.0 million. The Company expects to pay approximately $1.0 million towards the settlement, the amount remaining on its self-insured retention/deductible, and the Company’s insurers will pay the remaining balance. The proposed settlement requires both preliminary and final approval by the court. On October 1, 2019, a shareholder derivative complaint captioned Noel Borg v. Dean Irwin, et. al Settlement Agreements with the Department of Justice and Participating States As previously announced on December 28, 2020, the Company entered into a Settlement Agreement with the U.S., acting through the Department of Justice (“DOJ”) and on behalf of the Office of Inspector General (“OIG”), and other settlement agreements with certain state attorneys general to resolve investigations and a related civil action concerning its marketing of the DABRA laser system and DABRA-related remuneration to certain physicians. Pursuant to the terms of the Settlement Agreement and the agreements with the participating states, (a) if the Company’s revenue exceeds $10 million in any of fiscal years 2021-2024, the Company also is required to pay for the corresponding year: $500,000 for 2021, $750,000 for 2022, $1 million for 2023, and $1.25 million for 2024; (b) if the Company is acquired or is otherwise involved in a change in control transaction before the end of 2024, the Company is required to pay an additional settlement amount of $5 million, plus 4% of the value attributed to the Company in the transaction, so long as the attributed value is in excess of $100 million, with the total change in control payment never to exceed $28 million; and (c) if the Company’s obligations under the Settlement Agreement are avoided by bankruptcy, the U.S. may rescind the releases and bring an action against the Company in which the Company agrees is not subject to an automatic stay, is not subject to any statute of limitations, estoppel or laches defense, and is a valid claim in the amount of $56 million, minus any prior change in control payments.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The unaudited interim condensed financial statements have been prepared on the same basis as the annual financial statements and reflect all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company’s condensed balance sheets, results of operations, cash flows and statements of stockholders’ equity for the periods presented. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any other future annual or interim period. The balance sheet as of December 31, 2020 included herein was derived from the audited financial statements as of that date after reclassifications related to discontinued operations. These unaudited condensed financial statements should be read in conjunction with the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 17, 2021.
Reclassifications	Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation.
Use of Estimates	Use of estimates The unaudited condensed financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States (“GAAP”).
Fair Value Measurements	Fair Value Measurements Fair value represents the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants and is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. A three-tier value hierarchy is used to identify inputs used in measuring fair value as follows: Level 1 – Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; Level 2 – Inputs other than the quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and Level 3 – Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions. The hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company measures its cash and cash equivalents and short-term investments at fair value.
Inventories	Inventories Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. Cost includes materials, labor and manufacturing overhead related to the purchase and production of inventories. The Company reduces the carrying value of inventories for those items that are potentially excess or obsolete based on changes in customer demand, technological developments or other economic factors. Catheters are manufactured in-house, and each catheter is tested at various stages of the manufacturing process for adherence to quality standards. Catheters that do not meet functionality specification at each test point are destroyed and immediately written off, with the expense recorded in cost of revenue in the statements of operations. Once manufactured, completed catheters that pass quality assurance are sent to a third-party for sterilization and sealed in a sterile container. Upon return from the third-party sterilizer, a sample of catheters from each batch are re-tested. If the sample tests are successful, the batch is accepted into finished goods inventory. If the sample tests are unsuccessful, the entire batch is written off with the expense recorded in cost of revenue in the statements of operations.
Revenue	Revenue The Company generates revenue from the sales of products and services. Product sales consist of the sales of catheters for use with the DABRA laser system. The Company has paused selling commercial product and is only selling catheters for use in the atherectomy clinical trial. The Company’s sales agreements generally do not include right-of-return provisions for any form of consideration, including partial refund or credit against amounts owed to the Company. Services and other revenue primarily consist of billable services, including fees related to DABRA laser commercial usage agreements. Catheter Revenue When engaged in commercial sales, the Company enters into a DABRA laser commercial usage agreement or DABRA laser placement acknowledgement with each customer that is supplied a DABRA laser, collectively the “usage agreement”, which provides for specific terms of continued use of the DABRA laser, including a nominal periodic fee. The terms of a usage agreement typically allow the Company to place a DABRA laser at a customer’s specified location without a specified contract term. Under the usage agreement terms, the Company retains all ownership rights to the DABRA laser and is permitted to request the return of the equipment within 10 business days of notification. While the periodic fees are nominal, the usage agreement provides the Company the exclusive rights to supply related single-use catheters to the customer which aggregate the majority of the product sales revenue. There are no specified minimum purchase commitments for the catheters. The Company recognizes revenue associated with the usage agreements and catheter supply arrangements in accordance with Financial Accounting Standards Board (“FASB”) “ Revenue from Contracts with Customers (Topic 606),” Distributor Transactions In certain markets outside the U.S., the Company sold products and provided services to customers through distributors that specialize in medical device products. The terms of sales transactions through distributors were generally consistent with the terms of direct sales to customers. The Company accounted for these transactions in accordance with the Company’s revenue recognition policy described herein. The following accounting policies are specifically related to the Company’s discontinued operations: Laser Sales The Company recognized revenue on laser sales at the point in time that control transferred to the customer. Control of the product typically transferred upon shipment. Warranty Service Revenue The Company typically provided a 12-month warranty with the purchase of its laser systems. Customers could extend the warranty period through the purchase of extended warranty service contracts. Extended warranty service contracts were sold with contract terms ranging from 12 to 60 months and covered periods after the end of the initial 12-month warranty period. The warranty provided the customer with maintenance services in addition to the assurance that the laser product complied with agreed-upon specifications. Therefore, the warranty service was treated as a separate performance obligation from the laser system. Warranty services were a stand-ready obligation, and the Company recognized revenue on a straight-line basis over the service contract term. Warranty service revenue was included in service and other revenue. Contract Costs The Company capitalized costs to obtain contracts that were considered incremental and recoverable, such as sales commissions. The capitalized costs were amortized to selling, general and administrative expense over the estimated period of benefit of the asset, which was the contract term. The Company elected to use the practical expedient to expense the costs to obtain a contract when the amortization period was less than one year. These lease arrangements contained one lease component (the laser) and one non-lease component (warranty service) for which the Company elected the practical expedient to not separate the non-lease component from the lease component. The Company accounted for the combined lease component as an operating lease and recognized lease income on a straight-line basis over the lease term. Rental Income The Company also derived income pursuant to its product operating lease agreements for its Pharos laser systems, prior to the sale of the Dermatology Business. Consequently, the Company retained title to the equipment. Depreciation expense on the leased lasers was recorded to cost of revenues on a straight-line basis. The costs to maintain the leased lasers were charged to cost of revenues as incurred. These lease arrangements contained one lease component (the laser) and one non-lease component (warranty service) for which the Company elected the practical expedient to not separate the non-lease component from the lease component. The Company accounted for the combined lease component as an operating lease and recognized lease income on a straight-line basis over the lease term.
Segment Information	Segment Information After the sale of the Dermatology Business, the Company began operating its business in one segment, which includes all activities related to the research, development and manufacture of the DABRA system. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company has evaluated recently issued accounting pronouncements and, based on its preliminary assessment, does not believe any will have a material impact on the condensed financial statements or related footnote disclosures.

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Summary of Assets and Liabilities Included as Discontinued Operations and Income (Loss) from Discontinued Operations	The following table summarizes the carrying amounts of the assets and liabilities included as discontinued operations in the condensed balance sheet at December 31, 2020 (in thousands): December 31, 2020 Assets of discontinued operations Accounts receivable, net $ 214 Inventories 1,341 Prepaid expenses and other current assets 158 Property and equipment, net 684 Other long-term assets 78 Total assets of discontinued operations $ 2,475 Liabilities of discontinued operations Accounts payable $ 100 Accrued expenses 201 Deferred revenue 2,487 Total liabilities of discontinued operations $ 2,788 The following table summarizes the major classes of items constituting income (loss) from discontinued operations in the condensed statements of operations for each of the periods presented (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Net revenues Product sales $ 140 $ 118 $ 852 $ 670 Service and other 349 729 1,748 2,259 Total net revenues 489 847 2,600 2,929 Cost of revenues Product sales 158 347 1,201 1,127 Service and other 238 504 1,089 1,296 Total cost of revenues 396 851 2,290 2,423 Gross income (loss) 93 (4 ) 310 506 Operating expenses Selling, general and administrative 330 236 1,110 958 Research and development 134 21 388 47 Total operating expenses 464 257 1,498 1,005 Operating loss (371 ) (261 ) (1,188 ) (499 ) Interest expense, net (22 ) (3 ) (94 ) (24 ) Loss from discontinued operations (393 ) (264 ) (1,282 ) (523 ) Gain on sale of the Dermatology Business 3,473 — 3,473 — Income (loss) from discontinued operations $ 3,080 $ (264 ) $ 2,191 $ (523 )

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consisted of the following (in thousands): September 30, 2021 December 31, 2020 Raw materials $ 884 $ 547 Work in process 60 270 Finished goods 53 60 Total inventories $ 997 $ 877

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2021
Property Plant And Equipment Net [Abstract]
Schedule of Property and Equipment	Property and equipment consisted of the following (in thousands): September 30, 2021 December 31, 2020 Lasers $ 3,151 $ 3,194 Machinery and equipment 812 834 Computer hardware and software 353 353 Construction in progress 209 51 Leasehold improvements 119 119 Automobiles 62 1,054 Furniture and fixtures 48 48 Property and equipment, gross 4,754 5,653 Accumulated depreciation (2,724 ) (3,126 ) Total property and equipment, net $ 2,030 $ 2,527

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2021
Payables And Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following (in thousands): September 30, 2021 December 31, 2020 Accrued legal expenses $ 1,393 $ 957 Compensation and related benefits 496 2,479 Accrued warranty (Note 8) 195 204 Other accrued expenses 548 507 Total accrued expenses $ 2,632 $ 4,147

Accrued Warranty (Tables)

Accrued Warranty (Tables)	9 Months Ended
	Sep. 30, 2021
Product Warranties Disclosures [Abstract]
Schedule of Warranty Accrual Included in Accrued Expenses	Activity in the warranty accrual is included in accrued expenses in the condensed balance sheets and consisted of the following (in thousands): Nine Months Ended September 30, 2021 Year Ended December 31, 2020 Balance at beginning of period $ 204 $ 234 Increase in warranty accrual — 19 Change in liability for pre-existing warranties — 4 Claims satisfied (9 ) (53 ) Total accrued warranty $ 195 $ 204

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Schedule of Maturities of Operating Lease Liabilities	Maturities of operating lease liabilities as of September 30, 2021 were as follows (in thousands): Years Ending December 31, 2021 (remaining three months) $ 132 2022 432 2023 445 2024 459 2025 472 2026 486 Thereafter 501 Total operating lease payments 2,927 Less: imputed interest (572 ) Total operating lease liabilities $ 2,355

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Schedule of Restricted Stock Units Activity	A summary of the restricted stock unit activity under the 2018 Plan is presented below: Restricted Stock Units Weighted Average Grant Date Fair Value Outstanding at December 31, 2020 33,548 $ 21.93 Granted 29,614 $ 3.99 Vested (1,845 ) $ 64.80 Forfeited (15,485 ) $ 14.67 Outstanding at September 30, 2021 45,832 $ 11.06
Schedule of Stock-based Compensation Expense Recorded in Operating Expenses	Stock-based compensation expense recorded in operating expenses was as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Selling, general and administrative $ 78 $ 757 $ 1,551 $ 2,424 Research and development 27 115 251 317 Stock-based compensation in operating expenses $ 105 $ 872 $ 1,802 $ 2,741
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Schedule of Options Activity	A summary of the stock option activity under the 2018 Equity Incentive Plan (the “ 2018 Plan”) 2018 Stock Compensation Plan Stock Options Weighted Average Exercise Price Weighted Average Remaining Life (in years) Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2020 124,171 $ 363.31 6.42 Forfeited (15,173 ) $ 87.28 Outstanding at September 30, 2021 108,998 $ 401.74 4.82 $ — Exercisable at September 30, 2021 95,096 $ 455.95 4.32 $ — Vested and expected to vest at September 30, 2021 108,998 $ 401.74 4.80 $ —
Stock Option Activity Two Thousand Twenty Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Schedule of Options Activity	A summary of the stock option activity under the 2020 Inducement Equity Incentive Plan (the “2020 Plan”) is presented below: Stock Options Weighted Average Exercise Price Weighted Average Remaining Life (in years) Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2020 18,000 $ 25.50 9.24 Outstanding at September 30, 2021 18,000 $ 25.50 8.50 $ — Exercisable at September 30, 2021 6,750 $ 25.50 8.50 $ — Vested and expected to vest at September 30, 2021 18,000 $ 25.50 8.50 $ —
Two Thousand Eighteen Restricted Stock Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Schedule of Restricted Stock Awards Activity	A summary of the restricted stock award activity under the 2018 Plan is presented below: Restricted Stock Awards Weighted Average Grant Date Fair Value Outstanding at December 31, 2020 286,161 $ 4.77 Granted 103,939 $ 4.82 Vested (31,388 ) $ 6.96 Forfeited (50,082 ) $ 5.10 Outstanding at September 30, 2021 308,630 $ 4.51
Two Thousand Twenty Restricted Stock Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Schedule of Restricted Stock Awards Activity	A summary of the restricted stock award activity under the 2020 Plan is presented below: Restricted Stock Awards Weighted Average Grant Date Fair Value Outstanding at December 31, 2020 4,375 $ 25.50 Vested (625 ) $ 25.50 Outstanding at September 30, 2021 3,750 $ 25.50

Organization and Nature of Op_2

Organization and Nature of Operations - Additional Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Accumulated deficit	$ 169,985		$ 153,202
Net cash used in operating activities for continuing and discontinued operations	21,914	$ 18,890
Cash and cash equivalents	$ 20,616		$ 23,906

Significant Accounting Polici_3

Significant Accounting Policies - Additional Information (Details)	9 Months Ended
	Sep. 30, 2021Segment
Number of operating segments	1
Minimum [Member]
Regular warranty service contracts term	12 months
Maximum [Member]
Extended warranty service contracts term	60 months
Capitalized contract cost amortization period	1 year

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Details) - USD ($)	Aug. 16, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Common stock, shares issued		7,042,000		7,042,000		3,189,000
Common stock, par value		$ 0.0001		$ 0.0001		$ 0.0001
Gain on disposition of business		$ 3,473,000		$ 3,473,000
Dermatology [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Depreciation expense		100,000	$ 100,000	300,000	$ 300,000
Capital expenditure				0	0
Stock based compensation expense			14,000	18,000	100,000
Stock based compensation expense capitalized to inventory and property and equipment		4,000	$ 30,000	100,000	$ 100,000
Dermatology [Member] | Disposition by Sale [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Gain on disposition of business		$ 3,500,000		$ 3,500,000
Dermatology [Member] | Discontinued Operations [Member] | Disposition by Sale [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Cash on disposition of business	$ 3,700,000
Broker and legal fees on disposal	$ 200,000
Dermatology [Member] | Discontinued Operations [Member] | Disposition by Sale [Member] | Warrant [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Common stock, shares issued	74,247
Common stock, par value	$ 2.99
Warrant expiry period	5 years
Warrant	$ 100,000
Expected volatility rate	104.55%
Risk free interest rate	0.32%
Expected dividend rate	0.00%
Expected term	2 years 6 months

Discontinued Operations - Summa

Discontinued Operations - Summary of Carrying Amounts of Assets and Liabilities Included as Discontinued Operations in Condensed Balance Shee (Details) $ in Thousands	Dec. 31, 2020USD ($)
Assets of discontinued operations
Accounts receivable, net	$ 214
Inventories	1,341
Prepaid expenses and other current assets	158
Property and equipment, net	684
Other long-term assets	78
Total assets of discontinued operations	2,475
Liabilities of discontinued operations
Accounts payable	100
Accrued expenses	201
Deferred revenue	2,487
Total liabilities of discontinued operations	$ 2,788

Discontinued Operations - Sum_2

Discontinued Operations - Summary of Major Classes of Items Constituting Income (Loss) from Discontinued Operations in Condensed Statements of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Total net revenues	$ 489	$ 847	$ 2,600	$ 2,929
Total cost of revenues	396	851	2,290	2,423
Gross income (loss)	93	(4)	310	506
Total operating expenses	464	257	1,498	1,005
Operating loss	(371)	(261)	(1,188)	(499)
Interest expense, net	(22)	(3)	(94)	(24)
Loss from discontinued operations	(393)	(264)	(1,282)	(523)
Gain on disposition of business	3,473		3,473
Income (loss) from discontinued operations	3,080	(264)	2,191	(523)
Service and Other [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Total net revenues	349	729	1,748	2,259
Total cost of revenues	238	504	1,089	1,296
Selling, General And Administrative [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Total operating expenses	330	236	1,110	958
Research And Development [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Total operating expenses	134	21	388	47
Product Sales [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Total net revenues	140	118	852	670
Total cost of revenues	$ 158	$ 347	$ 1,201	$ 1,127

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Money Market Funds [Member] | Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value disclosure of cash equivalents	$ 9.4	$ 18.4

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 884	$ 547
Work in process	60	270
Finished goods	53	60
Total inventories	$ 997	$ 877

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 4,754	$ 5,653
Accumulated depreciation	(2,724)	(3,126)
Total property and equipment, net	2,030	2,527
Lasers
Property Plant And Equipment [Line Items]
Property and equipment, gross	3,151	3,194
Machinery and Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	812	834
Computer Hardware and Software
Property Plant And Equipment [Line Items]
Property and equipment, gross	353	353
Construction in Progress
Property Plant And Equipment [Line Items]
Property and equipment, gross	209	51
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	119	119
Automobiles
Property Plant And Equipment [Line Items]
Property and equipment, gross	62	1,054
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 48	$ 48

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Property Plant And Equipment [Line Items]
Depreciation expense	$ 0.2	$ 0.4	$ 0.7	$ 1.3
Automobiles | Selling, General and Administrative Expenses [Member]
Property Plant And Equipment [Line Items]
Gain on Sale of Property and Equipment			$ 0.5

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Payables And Accruals [Abstract]
Accrued legal expenses	$ 1,393	$ 957
Compensation and related benefits	496	2,479
Accrued warranty (Note 8)	195	204	$ 234
Other accrued expenses	548	507
Total accrued expenses	$ 2,632	$ 4,147

Accrued Warranty - Schedule of

Accrued Warranty - Schedule of Warranty Accrual Included in Accrued Expenses (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Product Warranties Disclosures [Abstract]
Balance at beginning of period, Accrued warranty	$ 204	$ 234
Increase in warranty accrual		19
Change in liability for pre-existing warranties		4
Claims satisfied	(9)	(53)
Balance at ending of period, Accrued warranty	$ 195	$ 204

Accrued Warranty - Additional I

Accrued Warranty - Additional Information (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Product Warranty Liability [Line Items]
Accrued warranty (Note 8)	$ 195	$ 204	$ 234
Catheters [Member] | Product Recall [Member]
Product Warranty Liability [Line Items]
Accrued warranty (Note 8)	$ 100	$ 100

Paycheck Protection Program P_2

Paycheck Protection Program Promissory Note - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	May 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Gain on extinguishment of promissory note				$ 2,023,000
Promissory Note | Corona Virus Aid Relief Economic Security Act
Paycheck protection program, amount	$ 2,000,000
Interest rate	1.00%
Payments due, beginning date	Nov. 1, 2020
Payments due, ending date	2022-05
Gain on extinguishment of promissory note				2,000,000
Interest expense		$ 0	$ 5,000	$ 10,000	$ 8,000
Debt instrument, description				payments would have been due beginning August 2021, and the principal amount, along with unpaid interest, would have been due in May 2022. The principal and interest could be forgiven if the proceeds were used for forgivable purposes as defined by the terms in the PPP Promissory Note.

Leases - Additional Information

Leases - Additional Information (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)Lease	Sep. 30, 2020USD ($)
Operating Leased Assets [Line Items]
Number of leases | Lease			2
Operating lease, discount rate	7.00%		7.00%
Operating lease, weighted average remaining lease term	6 years 3 months 18 days		6 years 3 months 18 days
Operating lease expense	$ 0.1	$ 0.1	$ 0.4	$ 0.4
Operating lease , cash payment	0.1	0.1	0.4	0.4
Amortization for operating lease right-of-use-assets	$ 0.1	$ 0.1	$ 0.3	$ 0.3
Office Building [Member]
Operating Leased Assets [Line Items]
Lease expiration period			2027
Manufacturing Facility [Member]
Operating Leased Assets [Line Items]
Lease expiration period month and year			2021-12

Leases - Schedule of Maturities

Leases - Schedule of Maturities of Operating Lease Liabilities (Details) $ in Thousands	Sep. 30, 2021USD ($)
Leases [Abstract]
2021 (remaining three months)	$ 132
2022	432
2023	445
2024	459
2025	472
2026	486
Thereafter	501
Total operating lease payments	2,927
Less: imputed interest	(572)
Total operating lease liabilities	$ 2,355

Net Loss per Share - Additional

Net Loss per Share - Additional Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Loss allocated to participating securities	$ 0
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive share equivalents excluded from computation of diluted net loss per share	126,998	144,851
Warrants [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive share equivalents excluded from computation of diluted net loss per share	2,419,280	2,345,033
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive share equivalents excluded from computation of diluted net loss per share	45,832	20,678
Restricted Stock Awards (RSAs) [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive share equivalents excluded from computation of diluted net loss per share	312,380	5,000
Employee Stock Purchase Plan [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive share equivalents excluded from computation of diluted net loss per share	10,462	3,772

Equity Offerings - Additional I

Equity Offerings - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	Feb. 28, 2021	Aug. 31, 2021	Jun. 30, 2021	Sep. 30, 2021	Dec. 31, 2020
Class Of Stock [Line Items]
Common stock, shares authorized				300,000,000	300,000,000
Common stock, par value				$ 0.0001	$ 0.0001
ATM Offering
Class Of Stock [Line Items]
Common stock, shares authorized	35,768	1,139,306	2,582,019
Common stock, par value	$ 8.39	$ 4	$ 4.29
Proceeds from issuance of common stock	$ 0.3	$ 4.4	$ 10.6
Offering fees and other expenses	$ 0.2

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Options Activity (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Weighted Average Remaining Life (in years)
Weighted Average Remaining Life (in years)	1 year 10 months 24 days
Stock Options [Member]
Options outstanding
Beginning balance	124,171
Forfeited	(15,173)
Ending balance	108,998	124,171
Exercisable at the end of the period	95,096
Vested and expected to vest at the end of the period	108,998
Weighted Average Remaining Life (in years)
Weighted Average Remaining Life (in years)	4 years 9 months 25 days	6 years 5 months 1 day
Exercisable at the end of the period	4 years 3 months 25 days
Vested and expected to vest at the end of the period	4 years 9 months 18 days
Weighted Average Exercise Price
Beginning balance	$ 363.31
Forfeited	87.28
Ending balance	401.74	$ 363.31
Exercisable at the end of the period	455.95
Vested and expected to vest at the end of the period	$ 401.74
Stock Option Activity Two Thousand Twenty Equity Incentive Plan [Member]
Options outstanding
Beginning balance	18,000
Ending balance	18,000	18,000
Exercisable at the end of the period	6,750
Vested and expected to vest at the end of the period	18,000
Weighted Average Remaining Life (in years)
Weighted Average Remaining Life (in years)	8 years 6 months	9 years 2 months 26 days
Exercisable at the end of the period	8 years 6 months
Vested and expected to vest at the end of the period	8 years 6 months
Weighted Average Exercise Price
Beginning balance	$ 25.50
Ending balance	25.50	$ 25.50
Exercisable at the end of the period	25.50
Vested and expected to vest at the end of the period	$ 25.50

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Restricted Stock Units
Beginning balance | shares	33,548
Granted | shares	29,614
Vested | shares	(1,845)
Forfeited | shares	(15,485)
Ending balance | shares	45,832
Weighted Average Grant Date Fair Value
Beginning balance | $ / shares	$ 21.93
Granted | $ / shares	3.99
Vested | $ / shares	64.80
Forfeited | $ / shares	14.67
Ending balance | $ / shares	$ 11.06

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule of Restricted Stock Awards Activity (Details) - Restricted Stock Awards (RSAs) [Member]	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Two Thousand Eighteen Restricted Stock Plan
Restricted Stock Units
Beginning balance | shares	286,161
Granted | shares	103,939
Vested | shares	(31,388)
Forfeited | shares	(50,082)
Ending balance | shares	308,630
Beginning balance | $ / shares	$ 4.77
Granted | $ / shares	4.82
Vested | $ / shares	6.96
Forfeited | $ / shares	5.10
Ending balance | $ / shares	$ 4.51
Two Thousand Twenty Restricted Stock Plan
Restricted Stock Units
Beginning balance | shares	4,375
Vested | shares	(625)
Ending balance | shares	3,750
Beginning balance | $ / shares	$ 25.50
Vested | $ / shares	25.50
Ending balance | $ / shares	$ 25.50

Stock-Based Compensation - Sc_4

Stock-Based Compensation - Schedule of Stock-based Compensation Expense Recorded in Operating Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation in operating expenses	$ 105	$ 872	$ 1,802	$ 2,741
Selling, General And Administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation in operating expenses	78	757	1,551	2,424
Research And Development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation in operating expenses	$ 27	$ 115	$ 251	$ 317

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation			$ 1,967	$ 3,044
Weighted Average Remaining Life (in years)			1 year 10 months 24 days
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation	$ 5,000	$ 48,000	$ 100	$ 100
Unrecognized compensation expense for stock options issued	400		$ 400
Weighted Average Remaining Life (in years)			4 years 9 months 25 days		6 years 5 months 1 day
Restricted Stock Units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense for stock options issued	300		$ 300
Weighted-average recognized period			2 years
Restricted Stock Awards (RSAs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense for stock options issued	$ 800		$ 800
Weighted-average recognized period			2 years 4 months 24 days

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)	Nov. 12, 2021	Dec. 28, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Loss Contingencies [Line Items]
Total net revenues			$ 5,000	$ 68,000	$ 17,000	$ 259,000
Settlement Agreement
Loss Contingencies [Line Items]
Settlement amount , year 2021		$ 500,000
Settlement year one		2021
Settlement amount , year 2022		$ 750,000
Settlement year two		2022
Settlement amount , year 2023		$ 1,000,000
Settlement year three		2023
Settlement amount , year 2024		$ 1,250,000
Settlement year four		2024
Business acquisition, settlement amount		$ 5,000,000
Business acquisition additional settlement percentage		4.00%
Business acquisition, transaction costs		$ 100,000,000
Business acquisition change In control payments		28,000,000
Settlement claim		56,000,000
Settlement Agreement | Maximum [Member]
Loss Contingencies [Line Items]
Total net revenues		$ 10,000,000
Securities Litigation | Subsequent Event
Loss Contingencies [Line Items]
Settlement provided for a payment to plaintiff class	$ 10,000,000
Expected amount contribute to settlement	$ 1,000,000